Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ).
J Aerosol Med Pulm Drug Deliv
; 28(5): 406-10, 2015 Oct.
Article
en En
| MEDLINE
| ID: mdl-26327351
ABSTRACT
Parenteral IFN-γ was unsuccessful as a treatment for pulmonary fibrosis. Inhaled IFN-γ targeted to the lungs may be more effective. Our patient, a 56-year-old male with biopsy proven usual interstitial pneumonia (UIP) and declining pulmonary function tests (PFTs) was initially diagnosed with idiopathic pulmonary fibrosis (IPF). He enrolled in a 2-year research protocol and was treated with inhaled IFN-γ (100 µg, Actimmune, Horizon Pharma, Deerfield, IL) 3 times per week. After completion of the protocol, he was able to secure the drug and continued therapy for a total of 7 years. He felt better, returning to work. His only complaint was transient cough during inhalation. PFTs improved (e.g., DLCO, 58% at baseline, 81% at 2 years, 69% currently). Clinical monitoring showed preserved exercise tolerance and stable CT scans. He was ultimately diagnosed (year 5) with scleroderma-like connective tissue disease after he developed sclerodactyly and a positive antinuclear antibody. Inhaled IFN-γ was well tolerated for 7 years and may stabilize fibrotic lung disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Interferón gamma
/
Fibrosis Pulmonar Idiopática
Tipo de estudio:
Guideline
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Aerosol Med Pulm Drug Deliv
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2015
Tipo del documento:
Article